» Articles » PMID: 24286077

Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2013 Nov 29
PMID 24286077
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Liver is a vital organ responsible for plethora of functions including detoxification, protein synthesis, and the production of biochemicals necessary for the sustenance of life. Therefore, patients with chronic liver diseases such as viral hepatitis, liver cirrhosis, and hepatocellular carcinoma need immediate attention to sustain life and as a result are often exposed to the prolonged treatment with drugs/herbal medications. Lack of site-specific delivery of these medications to the hepatocytes/nonparenchymal cells and adverse effects associated with their off-target interactions limit their continuous use. This calls for the development and fabrication of targeted delivery systems which can deliver the drug payload at the desired site of action for defined period of time. The primary aim of drug targeting is to manipulate the whole body distribution of drugs, that is, to prevent distribution to non-target cells and concomitantly increase the drug concentration at the targeted site. Carrier molecules are designed for their selective cellular uptake, taking advantage of specific receptors or binding sites present on the surface membrane of the target cell. In this review, various aspects of liver targeting of drug molecules and herbal medications have been discussed which elucidate the importance of delivering the drugs/herbal medications at their desired site of action.

Citing Articles

Enhancing Anti-PD-1 Immunotherapy by Targeting MDSCs via Hepatic Arterial Infusion in Breast Cancer Liver Metastases.

Kim M, Powers C, Fisher D, Ku A, Neznanov N, Safina A Cancers (Basel). 2024; 16(21).

PMID: 39518148 PMC: 11545300. DOI: 10.3390/cancers16213711.


Macrophage membrane coated discoidal polymeric particles for evading phagocytosis.

Aryal S, Park S, Cho H, Choi K, Choi M, Park Y Biomed Eng Lett. 2024; 14(5):1113-1124.

PMID: 39220034 PMC: 11362442. DOI: 10.1007/s13534-024-00396-x.


Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine.

Bakrania A, To J, Zheng G, Bhat M Gastro Hep Adv. 2024; 2(7):948-963.

PMID: 39130774 PMC: 11307499. DOI: 10.1016/j.gastha.2023.07.012.


Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.

Unagolla J, Das S, Flanagan R, Oehler M, Menon J Int J Pharm. 2024; 660:124381.

PMID: 38917958 PMC: 11246230. DOI: 10.1016/j.ijpharm.2024.124381.


Advancing liposome technology for innovative strategies against malaria.

Miatmoko A, Tarimi Octavia R, Araki T, Annoura T, Sari R Saudi Pharm J. 2024; 32(6):102085.

PMID: 38690211 PMC: 11059525. DOI: 10.1016/j.jsps.2024.102085.


References
1.
Clerc T, Sbarra V, Botta-Fridlund D, Lafont H, Gauthier A, Chanussot F . Bile salt secretion by hepatocytes incubated with bile salts and liposomes or low density lipoproteins. Life Sci. 1995; 56(4):277-86. DOI: 10.1016/0024-3205(94)00922-8. View

2.
Liu D, Hu Q, Song Y . Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta. 1995; 1240(2):277-84. DOI: 10.1016/0005-2736(95)00184-0. View

3.
Opanasopit P, Nishikawa M, Hashida M . Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst. 2003; 19(3):191-233. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i3.10. View

4.
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

5.
Beljaars L, Poelstra K, Molema G, Meijer D . Targeting of sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. J Hepatol. 1998; 29(4):579-88. DOI: 10.1016/s0168-8278(98)80153-0. View